Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT ODT versus ENLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT ODT versus ENLON.
ARICEPT ODT vs ENLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible acetylcholinesterase inhibitor, increasing acetylcholine concentration in the synaptic cleft of central cholinergic neurons.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting neuromuscular transmission.
5 mg orally once daily; may increase to 10 mg once daily after 4-6 weeks.
Intravenous: 0.1 mg/kg followed by 1-2 mg/min infusion for reversal of neuromuscular blockade; adjust based on twitch response.
None Documented
None Documented
Terminal elimination half-life: 70 hours (range 50-80 hours). Clinical context: Steady-state achieved in 15-21 days; once-daily dosing maintains therapeutic concentrations.
Terminal elimination half-life of 1.5-2.5 hours; prolonged in renal impairment and elderly patients
Renal: 57% (as unchanged drug and metabolites); Fecal: 15%; Biliary: minor
Primarily renal excretion of unchanged drug (85-95%), with minor fecal elimination (<5%)
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor